TP53 and acute lymphoblastic leukemia: Thymoquinone inhibited p53-mutated acute lymphoblastic leukemia (ALL) cells via the activation of a p73-dependent mitochondrial and cell cycle checkpoint signaling pathway; this pathway subsequently targets the anti-apoptotic and epigenetic integrator UHRF1, which is essential for cell cycle progression [28].